ストックスクリーナーアプリを入手
2.63
9.13%
0.22
前日終値:
$2.41
開ける：
$2.41
24時間の取引高:
1.39M
Relative Volume:
1.96
時価総額：
$195.22M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-15.33
EPS:
-0.1716
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
+11.91%
1か月 パフォーマンス:
+42.16%
6か月 パフォーマンス:
-66.62%
1年 パフォーマンス:
-82.81%
1日の値動き範囲:
$2.3612
$2.75
1週間の範囲:
$2.10
$2.8655
52週間の値動き範囲:
$1.60
$16.90
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.63 | 174.02M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss o - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
Perspective Therapeutics (CATX) Prepares for Q1 Earnings Announcement - GuruFocus
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Barclays PLC - Defense World
Mariner LLC Invests $150,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Inc (AMEX: CATX): Down -84.76% In 2025, Outlook Remains Negative - Stocksregister
Legal & General Group Plc Has $155,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors - marketscreener.com
Perspective Therapeutics (CATX) Launches Initial Patient Treatme - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors - The Manila Times
Groundbreaking Cancer Treatment Trial Launches: Perspective's FAP-α Targeted Alpha Therapy Shows Promise - Stock Titan
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Perspective Therapeutics Inc (CATX) - Sete News
A company insider recently bought 22,026 shares of Perspective Therapeutics Inc [CATX]. Should You Buy? - knoxdaily.com
Perspective Therapeutics Inc (CATX)’s stock rises to 2.33 per share - uspostnews.com
Perspective Therapeutics Announces Acceptance of VMT-?-NET and V - GuruFocus
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting - Nasdaq
Major Breakthrough: Perspective Therapeutics to Present Novel Cancer Treatment Data at ASCO 2025 - Stock Titan
CATX Stock on the Rise: A Promising Investment - investchronicle.com
Truist Financial Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR - The Globe and Mail
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph
Perspective Therapeutics to Provide Business Highlights and Repo - GuruFocus
Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat
Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener
Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma | CATX Stock News - GuruFocus
Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
0.22%
大文字化:
|
ボリューム (24 時間):